Platelet transfusion is currently the primary medical treatment for reducing thrombocytopenia in patients with inherited thrombocytopenias. To evaluate whether stimulating megakaryopoiesis could increase platelet count in these conditions, we treated patients with a severe thrombocytopenia induced by MYH9 mutations (MYH9-related disease) with a nonpeptide thrombopoietin receptor agonist, eltrombopag. Twelve adult patients with MYH9-RD and platelet counts of less than 50 ؋ 10 9 /L received 50 mg of eltrombopag orally per day for 3 weeks. Patients who achieved a platelet count higher than 150 ؋ 10 9 /L stopped therapy, those with 100 to 150 platelets ؋ 10 9 /L continued treatment at the same eltrombopag dose for 3 additional weeks, while those with less than 100 platelets ؋ 10 9 /L increased the eltrombopag dose to 75 mg for 3 weeks.